DE60317039D1 - Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben - Google Patents

Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben

Info

Publication number
DE60317039D1
DE60317039D1 DE60317039T DE60317039T DE60317039D1 DE 60317039 D1 DE60317039 D1 DE 60317039D1 DE 60317039 T DE60317039 T DE 60317039T DE 60317039 T DE60317039 T DE 60317039T DE 60317039 D1 DE60317039 D1 DE 60317039D1
Authority
DE
Germany
Prior art keywords
peptidic
salts
preparation
formula
boric acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60317039T
Other languages
English (en)
Other versions
DE60317039T2 (de
Inventor
David Jonathan Madge
Mark Dolman
Sophie Marie Combe-Marzelle
John Joseph Amrad Deadman
Anthony James Kennedy
Sanjay Kumar Kakkar
Armin Girindus Ag Walter
Alfred Girindus Ag Olbrich
Dieter Krimmer
Andrea Maria Weiland-Weibel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigen Ltd
Original Assignee
Trigen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220764A external-priority patent/GB0220764D0/en
Priority claimed from GB0220822A external-priority patent/GB0220822D0/en
Priority claimed from GB0307817A external-priority patent/GB0307817D0/en
Priority claimed from GB0311237A external-priority patent/GB0311237D0/en
Priority claimed from GB0315691A external-priority patent/GB0315691D0/en
Application filed by Trigen Ltd filed Critical Trigen Ltd
Application granted granted Critical
Publication of DE60317039D1 publication Critical patent/DE60317039D1/de
Publication of DE60317039T2 publication Critical patent/DE60317039T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60317039T 2002-09-09 2003-09-09 Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben Expired - Lifetime DE60317039T2 (de)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US485786 1983-04-18
GB0220764 2002-09-09
GB0220764A GB0220764D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0220822 2002-09-09
GB0220822A GB0220822D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0307817A GB0307817D0 (en) 2003-04-04 2003-04-04 Boronic acid compounds
GB0307817 2003-04-04
GB0311237 2003-05-16
GB0311237A GB0311237D0 (en) 2003-05-16 2003-05-16 Boronic acid compounds
GB0315691 2003-07-04
GB0315691A GB0315691D0 (en) 2003-07-04 2003-07-04 Boropeptides
US48578603P 2003-07-08 2003-07-08

Publications (2)

Publication Number Publication Date
DE60317039D1 true DE60317039D1 (de) 2007-12-06
DE60317039T2 DE60317039T2 (de) 2008-07-31

Family

ID=31721886

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60317039T Expired - Lifetime DE60317039T2 (de) 2002-09-09 2003-09-09 Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
DE60304956T Expired - Lifetime DE60304956T2 (de) 2002-09-09 2003-09-09 In parenteralen Formulierungen für die selektive Thrombininhibierung verwendbare Borsäuresalze
DE60305113T Expired - Lifetime DE60305113T2 (de) 2002-09-09 2003-09-09 Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60304956T Expired - Lifetime DE60304956T2 (de) 2002-09-09 2003-09-09 In parenteralen Formulierungen für die selektive Thrombininhibierung verwendbare Borsäuresalze
DE60305113T Expired - Lifetime DE60305113T2 (de) 2002-09-09 2003-09-09 Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung

Country Status (20)

Country Link
EP (8) EP1396269A1 (de)
JP (3) JP2006509034A (de)
KR (2) KR20050057295A (de)
CN (2) CN100553639C (de)
AT (3) ATE325611T1 (de)
AU (3) AU2003263328A1 (de)
BR (1) BR0314450A (de)
CA (3) CA2535792A1 (de)
CY (1) CY1105381T1 (de)
DE (3) DE60317039T2 (de)
DK (2) DK1400245T3 (de)
ES (2) ES2263924T3 (de)
HK (1) HK1063154A1 (de)
IL (1) IL167294A (de)
MX (2) MXPA05002661A (de)
NZ (2) NZ539333A (de)
PL (2) PL376439A1 (de)
PT (1) PT1396270E (de)
SI (2) SI1400245T1 (de)
WO (3) WO2004022072A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405267D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405280D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006059082A1 (en) * 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
BRPI0815713A2 (pt) * 2007-08-21 2015-02-10 Alza Corp Formulações lipossômicas de compostos de ácido borônico.
EA201070296A1 (ru) * 2007-08-21 2010-08-30 Алза Корпорейшн Липосомные композиции для введения in vivo соединений бороновой кислоты
US8389232B2 (en) * 2008-05-13 2013-03-05 The Regents Of The University Of California Fluorescence detection of poison oak oil
KR101690571B1 (ko) 2008-06-17 2016-12-28 밀레니엄 파머슈티컬스 인코퍼레이티드 보로네이트 에스테르 화합물 및 이의 제약학적 조성물
EP2355824A4 (de) * 2008-11-21 2012-11-07 Iroko Cardio Llc Verfahren zur reduzierung von thrombozytopenie und durch thrombozytopenie bedingter sterblichkeit
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
JP6662865B2 (ja) * 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
CN114685453A (zh) 2016-06-21 2022-07-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
CN109187155B (zh) * 2018-07-27 2021-08-13 临沂大学 一种水样中有效硼的提取纯化方法和一种硼同位素组成的测试方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN113121666B (zh) * 2021-03-10 2023-09-12 厦门大学 抗菌肽Scybaumancin105-127及其应用
CN114106346B (zh) * 2021-10-29 2023-04-18 重庆第二师范学院 一种稀土双金属电致化学发光材料及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5856695A (ja) 1981-09-28 1983-04-04 Nitto Boseki Co Ltd 新規なトロンビン測定用基質
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5574014A (en) 1988-04-28 1996-11-12 Thrombosis Research Institute Inhibitors of trypsin-like enzymes
IL90244A (en) 1988-05-11 1993-05-13 Du Pont Merck Pharma Peptide-drug compositions, for buccal and nasal administration, containing :-aminoboronic acid derivatives
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
US5648338A (en) 1990-11-06 1997-07-15 Thrombosis Research Institute Inhibitors and substrates of thrombin
GB9024129D0 (en) 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
CA2109526C (en) 1991-04-30 1998-01-20 Dwight M. Peterson Liquid detergents with an aryl boroic acid
GB9224702D0 (en) 1992-11-25 1993-01-13 Thrombosis Res Inst Boronic ester synthesis
FR2701951B1 (fr) * 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2153656A1 (en) 1993-03-03 1994-09-15 Nigel Scott Cook Peptide boronic acid derivatives having protease inhibiting activity
WO1994021650A1 (en) * 1993-03-24 1994-09-29 The Du Pont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
SE9900043D0 (sv) 1999-01-11 1999-01-11 Astra Ab New use
US5681978A (en) * 1993-07-07 1997-10-28 Washington State University Research Foundation Method for the stereocontrolled synthesis of stegobinone and useful borane intermediates
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
EP0722449A1 (de) * 1993-10-07 1996-07-24 The Du Pont Merck Pharmaceutical Company Boropeptid thrombin-inhibitoren, welche einen substituierten pyrrolidinring enthalten
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9502985D0 (en) 1995-02-16 1995-04-05 Thrombosis Res Inst Enzyme inhibitors
GB9515489D0 (en) 1995-07-28 1995-09-27 Sandoz Ltd Organic compounds
GB9613718D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
GB9724786D0 (en) * 1997-11-25 1998-01-21 Danbiosyst Uk Oral delivery system
AU5920400A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
SE9904483D0 (sv) 1999-12-08 1999-12-08 Astra Ab New use
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
CA2435146C (en) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
ES2263924T3 (es) 2006-12-16
DE60305113D1 (de) 2006-06-14
DK1400245T3 (da) 2006-08-28
DE60317039T2 (de) 2008-07-31
EP1695712A3 (de) 2008-01-09
EP1466916A1 (de) 2004-10-13
SI1400245T1 (sl) 2006-10-31
EP1396270B1 (de) 2006-05-10
CN100553639C (zh) 2009-10-28
AU2003263343A1 (en) 2004-03-29
EP1695711A3 (de) 2008-01-02
IL167294A (en) 2008-11-03
EP1561466A2 (de) 2005-08-10
DE60304956D1 (de) 2006-06-08
CA2535788A1 (en) 2004-03-18
DK1396270T3 (da) 2006-08-28
WO2004022071A1 (en) 2004-03-18
EP1466917A1 (de) 2004-10-13
WO2004022070A1 (en) 2004-03-18
PL376535A1 (pl) 2006-01-09
CN100447151C (zh) 2008-12-31
ES2264515T3 (es) 2007-01-01
EP1466916B1 (de) 2007-10-24
CN1681517A (zh) 2005-10-12
NZ539334A (en) 2007-11-30
KR20050057294A (ko) 2005-06-16
BR0314450A (pt) 2005-07-26
CA2535792A1 (en) 2004-03-18
EP1400245B1 (de) 2006-05-03
CA2536010A1 (en) 2004-03-18
ATE324899T1 (de) 2006-06-15
AU2003263328A1 (en) 2004-03-29
WO2004022072A1 (en) 2004-03-18
EP1400245A1 (de) 2004-03-24
AU2003263333A1 (en) 2004-03-29
CY1105381T1 (el) 2010-07-28
MXPA05002662A (es) 2005-09-20
PL376439A1 (en) 2005-12-27
EP1561466A3 (de) 2006-08-23
JP2006503903A (ja) 2006-02-02
DE60305113T2 (de) 2006-12-07
NZ539333A (en) 2007-02-23
SI1396270T1 (sl) 2006-10-31
EP1396270A1 (de) 2004-03-10
EP1695711A2 (de) 2006-08-30
MXPA05002661A (es) 2005-08-19
DE60304956T2 (de) 2007-01-25
ATE376551T1 (de) 2007-11-15
EP1695712A2 (de) 2006-08-30
CN1684693A (zh) 2005-10-19
JP2006511593A (ja) 2006-04-06
JP2006509034A (ja) 2006-03-16
PT1396270E (pt) 2006-08-31
ATE325611T1 (de) 2006-06-15
EP1396269A1 (de) 2004-03-10
KR20050057295A (ko) 2005-06-16
HK1063154A1 (en) 2004-12-17

Similar Documents

Publication Publication Date Title
DE60317039D1 (de) Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
ATE192153T1 (de) Amino-imidazo (4,5-c) chinoline
NO960949L (no) Tablettert flerdoseenhetsform inneholdende protonpumpeinhibitor
CA2069153A1 (en) Pharmaceutical composition
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
PL262105A1 (en) The method of manufacture of new derivatives of benzimidazole
AU2724292A (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-d-neuraminic acid
ATE250034T1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
SE0102057D0 (sv) New Salts I
IL81337A (en) Heptanoyl-glu-asp-ala-amino acid immunostimulants,process for their preparation and pharmaceutical compositions containing them
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
BR0014656A (pt) Agentes terapêuticos

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: MADGE, DAVID JONATHAN, LONDON WC1E 6AU, GB

Inventor name: DOLMAN, MARK, LONDON WC1E 6AU, GB

Inventor name: COMBE-MARZELLE, SOPHIE MARIE, LONDON SW1Y 4EL, GB

Inventor name: DEADMAN, JOHN JOSEPH, RICHMOND, VICTORIA 3121, AU

Inventor name: KENNEDY, ANTHONY JAMES, LONDON SW1Y 4EL, GB

Inventor name: KAKKAR, SANJAY KUMAR, LONDON SW1Y 4EL, GB

Inventor name: WALTER, ARMIN, 33777 HALLE (WESTF.), DE

Inventor name: OLBRICH, ALFRED, 33777 HALLE (WESTF.), DE

Inventor name: KRIMMER, DIETER, 9330 CHAM-STEINHAUSEN, CH

Inventor name: WEILAND-WEIBEL, ANDREA MARIA THERESIA, 6330 CH, CH

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KOENIG SZYNKA TILMANN VON RENESSE, 40549 DUESSELDO